pharmaceutical investing Johnson & Johnson reports 73% PSA response rate with investigational pasritamig-based immunotherapy combination in advanced prostate cancer
pharmaceutical investing Johnson & Johnson announces new Phase 2 nipocalimab study data in Sjögren's disease that reveal insights on importance of symptom improvements most valued by patients
pharmaceutical investing Johnson & Johnson announces ICOTYDE® delivers significant improvement in psoriatic arthritis disease activity among biologic-naive patients with once-daily targeted oral peptide
pharmaceutical investing Johnson & Johnson announces U.S. FDA Approval of RYBREVANT FASPRO as First and Only Dual-Targeted Therapy for Advanced Head and Neck Cancer
pharmaceutical investing Data Show Positive Survival and Patient Outcomes with Best-Practice Impella Support in HRPCI, in Contrast to CHIP-BCIS3 Study Results
pharmaceutical investing RYBREVANT FASPRO combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
pharmaceutical investing Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC molecule
pharmaceutical investing Johnson & Johnson announces ERLEADA® treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
pharmaceutical investing Johnson & Johnson Reports First Real-World VARIPULSE Pro Platform Data and 12-Month OMNYPULSE Platform Outcomes for Atrial Fibrillation Treatment at APHRS 2026
pharmaceutical investing Johnson & Johnson Launches Next-Generation Shockwave C2 Aero Fly Coronary IVL Catheter, Cutting IVL Treatment Time in Half
pharmaceutical investing Johnson & Johnson announces new data showing TREMFYA® is the only IL-23 to deliver durable fistula remission through 48 weeks in Crohn's disease with perianal fistula
pharmaceutical investing New TREMFYA® study shows consistent perianal fistula remission across key Crohn's disease patient subgroups
Brixton Metals Announces Upsize of Previously Announced Non-Brokered Private Placement to $8 Million and Closing of Second Tranche
BriaCell and BriaPro Present Positive Preclinical Immunotherapy Data Across Four Posters at SITC 2026
